ClearSight Innovations, a company cofounded by Michael Mrochen, PhD; Arthur B. Cummings FCS(SA), MMed(Ophth), FRCS(Edin); and Ronan Byrne, MBA, in 2013, is developing new technologies to allow accurate measurement of the eye in the hopes of moving cataract surgery outcomes to a new level. The company's prototype device for high-performance IOL power calculation, Mirricon (Figure 1), has been described at ophthalmology meetings; however, no data have been published yet.
Figure 1. The Mirricon uses ray
tracing to measure the anterior
and posterior surfaces of the
cornea and the axial length.
In short, the device produces accurate measurements of the anterior and posterior surfaces of the cornea and the lens as well as the axial length and deduces the refractive index of each medium. Based on these parameters, ray tracing is used to provide practitioners with IOL power calculation, essentially free of all assumptions.
According to Professor Mrochen, a recently completed proof of concept study (prospective study in 114 eyes) confirms the ability of the Mirricon system to improve refractive predictability in cataract surgery. At a recent Ophthalmology Innovation Summit meeting,1 he stated that the system eliminates refractive outliers and reduces the possibility of human error in IOL power calculation. Because it is “one solution for all kinds of eyes,” Mirricon can potentially save surgeons from having to use a variety of IOL calculators and may even exclude the need for pre-LASIK data, he said.
